Pediatrix raises 2025 Adjusted EBITDA outlook to $245 million to $255 million
Pediatrix Medical Group reported second-quarter 2025 net income of $39.3 million, or $0.46 per diluted share, compared with a net loss of $153.0 million a year earlier, which included impairment charges. Net revenue fell to $468.8 million from $504.3 million, mainly due to practice dispositions, and the company raised its full-year 2025 Adjusted EBITDA outlook to a range of $245 million to $255 million from $220 million to $240 million.
Key points
- Q2 2025 net revenue was $468.8 million, down from $504.3 million in Q2 2024, mainly due to practice dispositions.
- Q2 2025 net income was $39.3 million, or $0.46 per diluted share, versus a net loss of $153.0 million in Q2 2024.
- Q2 2025 Adjusted EPS was $0.53, compared with $0.34 a year earlier.
- Full-year 2025 Adjusted EBITDA outlook raised to $245 million to $255 million from $220 million to $240 million.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2025.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.